Lupin Gets Head Start On Brovana With US Authorized Generic
Launches Authorized Version Of Sunovion’s Arformoterol Tartrate Inhalation Solution
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.
You may also be interested in...
Lupin delivered a shaky Q3 as profit margins fell following complications with metformin and oseltamivir, but the firm appears confident that several impending high-value launches will set it back on the right track.
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.